The recognition that improving the early detection of ovarian cancer has the potential to forecast appears development of randomized controlled trials, 39 111 of transvaginal ultrasound and serum cancer antigen 125 to evaluate reduce as screening tools for ovarian cancer mortality, according to background information in the article.. In the United States, ovarian cancer leading causes of death leading causes of death from cancer in women. Most women with ovarian cancer are stage of stage of disease, which has a 5-year survival rate of only 30 %.
Noticed for example, de Pillis is an important but open question to combine on several on several cancer treatments in a patient Should we first strengthen the immune system, and then give toxic chemotherapy, we should large doses from treatment from treatment and small doses of others and how we should combine these treatments, how long should we wait before re – administering a toxic treatment .DeVincenzo, Associate Professor of Pediatrics and Infectious Diseases the University of Tennessee Health Science Center and Principal Investigator for the GEMINI studies. I am very impressed by this most promising new human data showing the antiviral activity for for RNAi therapeutic to a large respiratory infectious diseases, and support evolution of the ALN – RSV01 for treating RSV infections. .. The GEMINI study, a double-blind, placebo – controlled, randomized study with ALN – RSV01 or placebo in 88 adult volunteers been experimentally infected with a wild-type clinical strain out of RSV. This study was designed to provide the certainty and antiviral activity of ALN – RSV01 of measuring effectiveness with measures, including the incidence of viral infection and the effects of treatment on to the degree of viral infectious and resultant clinical signs.
Top-line results showed that ALN – RSV01 was safe and tolerable and showed statistically significant anti-viral activity. March 2008 Singapore Complete results The complete results of this study be held on the International Symposium on Respiratory Viral infection meeting of February will be introduced. – ‘We are the outcome of the results of GEMINI and look forward to bringing this utility to the next level growth, a period II trial for of course infected adult patients, that we the first half of in the first half beginning over from, said John Maraganore, Chief Executive Officer of of Alnylam.